Bayer
Pharmaceutical and chemicals group Bayer AG, which has acquired fellow German drugmaker Schering AG, posted a strong set on second-quarter 2006 results, with turnover from continuing operations rising 5.8% to 7.07 billion euros ($9.04 billion), earnings before interest, tax, depreciation and amortization and special items climbing 11.2% to 1.34 billion euros and EBIT before special items growing 14.1% to 928.0 million euros.
The figures, which include just one week of Schering's revenues of 144.0 million euros, came in just below consensus expectations and saw Bayer's share price dip 1% to 39.13 euros on the Frankfurt stock exchange. The stock, which was decimated on the market withdrawal of Baycol/Lipobay (cerivastatin) in 2000, has been creeping higher and had risen11% so far this year.
Bayer HealthCare sales up 12.7%
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze